Zai Lab and Innoviva Specialty Therapeutics Reports the NMPA’s Approval of Xacduro (sulbactam-durlobactam) for Hospital-Acquired and Ventilator-Associated Pneumonia
Shots:
- The NMPA has approved Zai Lab’s Xacduro for treating hospital-acquired bacterial pneumonia & ventilator-associated bacterial pneumonia (HABP/VABP) caused due to susceptible Acinetobacter baumannii-calcoaceticus complex in patients (≥18yrs.)
- The approval was supported by the P-III (ATTACK) study assessing the safety & efficacy of Xacduro vs colistin in patients infected by A. baumannii
- The study showed Xacduro’s non-inferiority vs colistin for 28-day all-cause mortality in carbapenem-resistant Acinetobacter infected patients, improved clinical cure rates plus a well-tolerated & favorable safety profile. The Chinese patients’ arm verified these findings on mortality & clinical response improvement
Ref: Zai Lab | Image: Zai Lab
Related News:- Innoviva Specialty Therapeutics’ Xacduro Receives the US FDA’s Approval for Pneumonia Caused by Acinetobacter
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
